LENZ Therapeutics, Inc. - Common Stock (LENZ)
CUSIP: 52635N103
Q2 2024 13F Holders as of 30 Jun 2024
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 31,105,155
- Total 13F shares
- 18,913,542
- Share change
- +2,674,401
- Total reported value
- $327,016,869
- Price per share
- $17.29
- Number of holders
- 63
- Value change
- +$45,118,057
- Number of buys
- 42
- Number of sells
- 14
Quarterly Holders Quick Answers
What is CUSIP 52635N103?
CUSIP 52635N103 identifies LENZ - LENZ Therapeutics, Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 52635N103:
Top shareholders of LENZ - LENZ Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. |
13F
|
Company |
13%
|
4,178,823
|
$93,313,118 | — | 31 Mar 2024 | |
| Alpha Wave Global, LP |
13F
|
Company |
12%
|
3,612,211
|
$80,660,672 | — | 31 Mar 2024 | |
| EcoR1 Capital, LLC |
3/4/5
13F
|
10%+ Owner · Company |
3.9%
from 13F
|
8,538,446
|
$34,836,860 | — | 06 Jan 2023 | |
| Samsara BioCapital, L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
8,497,067
|
$34,668,033 | — | 11 Apr 2022 | |
| Samsara BioCapital, LLC |
13F
|
Company |
3.9%
|
1,208,473
|
$26,985,202 | — | 31 Mar 2024 | |
| SECTORAL ASSET MANAGEMENT INC |
13F
|
Company |
3.4%
|
1,068,675
|
$23,863,513 | — | 31 Mar 2024 | |
| 72 Investment Holdings, LLC |
13F
|
Company |
3.3%
|
1,017,751
|
$22,726,380 | — | 31 Mar 2024 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
2.8%
|
864,942
|
$19,314,155 | — | 31 Mar 2024 | |
| RTW INVESTMENTS, LP |
13F
|
Company |
2.8%
|
863,389
|
$19,279,476 | — | 31 Mar 2024 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
1.8%
|
547,616
|
$12,228,265 | — | 31 Mar 2024 | |
| Versant Venture Capital VII, L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,598,789
|
$6,523,059 | — | 21 Mar 2024 | |
| BlackRock Finance, Inc. |
13F
|
Company |
0.77%
|
241,016
|
$5,381,887 | — | 31 Mar 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.67%
|
206,952
|
$4,621,238 | — | 31 Mar 2024 | |
| Alyeska Investment Group, L.P. |
13F
|
Company |
0.64%
|
199,602
|
$4,426,174 | — | 31 Mar 2024 | |
| JENNISON ASSOCIATES LLC |
13F
|
Company |
0.43%
|
134,740
|
$3,008,744 | — | 31 Mar 2024 | |
| Board of Trustees of The Leland Stanford Junior University |
13F
|
Company |
0.32%
|
100,438
|
$2,242,796 | — | 31 Mar 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.28%
|
88,218
|
$1,970,137 | — | 31 Mar 2024 | |
| Ikarian Capital, LLC |
13F
|
Company |
0.27%
|
85,000
|
$1,898,050 | — | 31 Mar 2024 | |
| STATE STREET CORP |
13F
|
Company |
0.21%
|
65,144
|
$1,454,666 | — | 31 Mar 2024 | |
| Prosight Management, LP |
13F
|
Company |
0.21%
|
65,000
|
$1,451,450 | — | 31 Mar 2024 | |
| BML Capital Management, LLC |
13F
|
Company |
0.21%
|
63,916
|
$1,427,244 | — | 31 Mar 2024 | |
| Phil Gutry |
3/4/5
|
CHIEF BUSINESS OFFICER |
—
class O/S missing
|
299,941
|
$1,223,759 | — | 11 Apr 2022 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.15%
|
46,866
|
$1,047,000 | — | 31 Mar 2024 | |
| Vivaldi Capital Management LP |
13F
|
Company |
0.19%
|
58,752
|
$924,169 | — | 31 Mar 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.13%
|
40,639
|
$907,469 | — | 31 Mar 2024 | |
| Katherine V Stultz |
3/4/5
|
CHIEF OPERATING OFFICER |
—
mixed-class rows
|
305,954
mixed-class rows
|
$881,362 | — | 24 Jun 2021 | |
| JACOBS LEVY EQUITY MANAGEMENT, INC |
13F
|
Company |
0.12%
|
37,176
|
$830,140 | — | 31 Mar 2024 | |
| Acuitas Investments, LLC |
13F
|
Company |
0.1%
|
31,488
|
$703,124 | — | 31 Mar 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0.09%
|
27,211
|
$607,645 | — | 31 Mar 2024 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.08%
|
23,537
|
$525,581 | — | 31 Mar 2024 | |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
|
Company |
0.07%
|
22,601
|
$504,680 | — | 31 Mar 2024 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.07%
|
21,920
|
$489,474 | — | 31 Mar 2024 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.05%
|
16,221
|
$362,215 | — | 31 Mar 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.04%
|
11,683
|
$260,881 | — | 31 Mar 2024 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.04%
|
11,181
|
$249,672 | — | 31 Mar 2024 | |
| CORNERCAP INVESTMENT COUNSEL INC |
13F
|
Company |
0.03%
|
9,350
|
$208,795 | — | 31 Mar 2024 | |
| BARCLAYS PLC |
13F
|
Company |
0.02%
|
6,563
|
$146,552 | — | 31 Mar 2024 | |
| Marquette Asset Management, LLC |
13F
|
Company |
0.02%
|
5,865
|
$130,966 | — | 31 Mar 2024 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.01%
|
4,598
|
$102,662 | — | 31 Mar 2024 | |
| UBS Group AG |
13F
|
Company |
0.01%
|
4,271
|
$95,372 | — | 31 Mar 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.01%
|
3,927
|
$87,690 | — | 31 Mar 2024 | |
| NEW YORK STATE COMMON RETIREMENT FUND |
13F
|
Company |
0.01%
|
3,490
|
$77,932 | — | 31 Mar 2024 | |
| AMERICAN INTERNATIONAL GROUP, INC. |
13F
|
Company |
0.01%
|
1,973
|
$44,051 | — | 31 Mar 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.01%
|
1,682
|
$37,559 | — | 31 Mar 2024 | |
| FMR LLC |
13F
|
Company |
0%
|
1,373
|
$30,659 | — | 31 Mar 2024 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
1,359
|
$30,346 | — | 31 Mar 2024 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0%
|
982
|
$21,928 | — | 31 Mar 2024 | |
| CITIGROUP INC |
13F
|
Company |
0%
|
750
|
$16,747 | — | 31 Mar 2024 | |
| NISA INVESTMENT ADVISORS, LLC |
13F
|
Company |
0%
|
644
|
$14,381 | — | 31 Mar 2024 | |
| GROUP ONE TRADING LLC |
13F
|
Company |
0%
|
571
|
$12,750 | — | 31 Mar 2024 |
Institutional Holders of LENZ Therapeutics, Inc. - Common Stock (LENZ) as of Q2 2024
As of 30 Jun 2024,
LENZ Therapeutics, Inc. - Common Stock (LENZ) was held by
63 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
18,913,542 shares.
The largest 10 holders included
RA CAPITAL MANAGEMENT, L.P., Alpha Wave Global, LP, EcoR1 Capital, LLC, Samsara BioCapital, LLC, SECTORAL ASSET MANAGEMENT INC, 72 Investment Holdings, LLC, BlackRock Inc., VANGUARD GROUP INC, Point72 Asset Management, L.P., and RTW INVESTMENTS, LP.
This page lists
63
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2024 vs Q1 2024 Across Filers
Q1 2024 holders
54
Q2 2024 holders
63
Holder diff
9
| Investor | Q1 2024 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2024 Value $ | Q2 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.